Literature DB >> 11563770

Growth hormone and insulin-like growth factor I axis and growth of children with different sickle cell anemia haplotypes.

S M Luporini1, I Bendit, R Manhani, O L Bracco, L Manzella, D Giannella-Neto.   

Abstract

BACKGROUND: The purpose of this study was to examine the relationships between growth in children with sickle cell anemia and the different beta-globin haplotypes, as well as components of the insulin-like growth factor (IGF)/insulin-like growth factor binding protein (IGFBP) axis. PATIENTS AND METHODS: Growth parameters and plasma concentrations of growth hormone (GH), IGF-I, and IGFBP-3 were studied in 41 children with sickle cell anemia whose haplotypes were defined.
RESULTS: Plasma concentrations of IGF-I (total, free, and free/total fraction) and IGFBP-3 were significantly reduced in all patients with sickle cell anemia compared with the healthy children. Patients with the CAR/CAR haplotype had significantly lower mean growth velocity compared with those with Ben/Ben. When the GH/IGF axis elements were compared in relation with the different haplotypes, total IGF-I levels in CAR/CAR patients were significantly lower compared with levels in patients with Ben/Ben. A positive correlation was found between hematocrit and total IGF-I and between fetal hemoglobin percentages and the z-scores for total IGF-I and IGFBP-3. There was a positive correlation between age, weight, height, bone age, and the various elements of the GH/IGF-I axis when all groups were considered, although the correlation was lost when the auxologic data were expressed as standard deviation score for age. Growth velocity and the z-score for growth velocity were not correlated with any element of the axis.
CONCLUSIONS: The positive relationship between hematocrit and fetal hemoglobin percentages with total IGF-I, free/total IGF-I, and IGFBP-3 in patients with sickle cell anemia could show that the delayed growth of these patients may be linked to intrinsic factors of the disease, which also determine the low circulating concentrations of the various elements of the GH/IGF-I axis. It is reasonable to assume that decrease of total IGF-I concentrations in patients with CAR/CAR haplotype is secondary to the severity of the disease.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11563770     DOI: 10.1097/00043426-200108000-00007

Source DB:  PubMed          Journal:  J Pediatr Hematol Oncol        ISSN: 1077-4114            Impact factor:   1.289


  6 in total

1.  Hydroxyurea and growth in young children with sickle cell disease.

Authors:  Sohail Rana; Patricia E Houston; Winfred C Wang; Rathi V Iyer; Jonathan Goldsmith; James F Casella; Caroline K Reed; Zora R Rogers; Myron A Waclawiw; Bruce Thompson
Journal:  Pediatrics       Date:  2014-09       Impact factor: 7.124

2.  Sickle cell anemia: clinical diversity and beta S-globin haplotypes.

Authors:  Sandra Regina Loggetto
Journal:  Rev Bras Hematol Hemoter       Date:  2013

Review 3.  Growth and Growth hormone - Insulin Like Growth Factor -I (GH-IGF-I) Axis in Chronic Anemias.

Authors:  Ashraf T Soliman; Vincenzo De Sanctis; Mohamed Yassin; Ashraf Adel
Journal:  Acta Biomed       Date:  2017-04-28

4.  Endocrine and metabolic complications in children and adolescents with Sickle Cell Disease: an Italian cohort study.

Authors:  V Mandese; E Bigi; P Bruzzi; G Palazzi; B Predieri; L Lucaccioni; M Cellini; L Iughetti
Journal:  BMC Pediatr       Date:  2019-02-11       Impact factor: 2.125

Review 5.  Mechanisms of Bone Impairment in Sickle Bone Disease.

Authors:  Paola Giordano; Flavia Urbano; Giuseppe Lassandro; Maria Felicia Faienza
Journal:  Int J Environ Res Public Health       Date:  2021-02-13       Impact factor: 3.390

Review 6.  The Role of the Multiple Hormonal Dysregulation in the Onset of "Anemia of Aging": Focus on Testosterone, IGF-1, and Thyroid Hormones.

Authors:  Marcello Maggio; Francesca De Vita; Alberto Fisichella; Fulvio Lauretani; Andrea Ticinesi; Graziano Ceresini; Anne Cappola; Luigi Ferrucci; Gian Paolo Ceda
Journal:  Int J Endocrinol       Date:  2015-12-08       Impact factor: 3.257

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.